Jenny N. Guo

Dr. Jenny N. Guo


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2023 in Journal of Endourology
Verified
Journal Article
Closed access
JGJenny N. Guo
Jenny N. Guo
NMNeil A. Mistry
Neil A. Mistry
MLMatthew S. Lee
Matthew S. Lee
NDNicholas Stewart Dean
Nicholas Stewart Dean
MAMark Assmus
Mark Assmus
AKAmy Krambeck
Amy Krambeck
INTRODUCTION: Holmium laser enucleation of the prostate (HoLEP) has evidenced-based advantages in treating benign prostatic hypertrophy (BPH) relative to other interventions. Unfortunately, adoption of HoLEP has remained relatively low in Medicare and National Surgical Quality Improvement Program (NSQIP) populations. HoLEP’s role as an inpatient surgical intervention is changing as advancements in the technique and systems have demonstrated the feasibility of same-day discharge. Thus, our objective was to evaluate national HoLEP trends in ambulatory surgery settings from 2016-2019. METHODS: The Nationwide Ambulatory Surgery Sample (NASS) is the largest national all-payer database of ambulatory surgical encounters, managed by the Agency for Healthcare Research and Quality. A cross-sectional, retrospective analysis of the 2016 and 2019 NASS was performed. Rates of BPH surgeries were calculated and stratified by age, census region, and primary payer to compare across time-points for trends. Chi-squared and two-sample t-tests were completed for categorical and continuous variables, respectively. RESULTS: The total number of ambulatory BPH surgeries fell 20% between 2016 (n=124,538) and 2019 (n=100,593). In 2016, HoLEP lagged behind photo-selective vaporization of the prostate (PVP) and Transurethral Resection of Prostate (TURP) with 4.7% of surgeries, but rose to the second most-common procedure in 2019 with 8.3% of total surgeries. TURP was the most common intervention (62.6% in 2016, 90.7% in 2019). Simple prostatectomy was the most expensive intervention. By US census region, more HoLEPs were done in the South (43.1% in 2016, 37.5% in 2019) and Midwest (26.8% in 2016, 31.7% in 2019). CONCLUSION: Overall, HoLEP uptake is increasing. HoLEP has replaced greenlight PVP as the second-most frequently used intervention. The rate of ambulatory HoLEPs has nearly doubled despite a general decrease in the number of surgeries.

23 November 2022 in Nature Reviews Urology
Verified
Journal Article
Closed access
PDF file
MLMatthew S. Lee
Matthew S. Lee
MAMark A. Assmus
Mark A. Assmus
JGJenny N. Guo
Jenny N. Guo
MSMohammad R. Siddiqui
Mohammad R. Siddiqui
ARAshley E. Ross
Ashley E. Ross
AKAmy E. Krambeck
Amy E. Krambeck

1 December 2023 in Journal of Endourology
Verified
Journal Article
Closed access
NDNicholas Stewart Dean
Nicholas Stewart Dean
MLMatthew S. Lee
Matthew S. Lee
MAMark Assmus
Mark Assmus
JGJenny N. Guo
Jenny N. Guo
PXPerry Xu
Perry Xu
AKAmy Krambeck
Amy Krambeck
Introduction: Holmium laser enucleation of the prostate (HoLEP) is routinely performed with a 24, 26, or a 28 French (F) scope. Proponents of the larger scopes propose that a bigger sheath size allows for superior flow and visibility leading to a more efficient operation and better hemostasis. Those utilizing the smaller scopes suggest the lower profile is less traumatic, resulting in lower stricture rates and temporary incontinence. We sought to compare outcomes of ambulatory HoLEP using the 24F and 28F laser scope. Materials and Methods: From May 2022 to March 2023, we randomized patients undergoing HoLEP (0.05) scopes. Procedural duration and efficiencies were not different between groups (all p>0.05). The 28F scope was associated with improved surgeon-graded irrigation flow and visibility (p0.05). Conclusions: We identified no clear advantage of scope size with regards to intra-operative or post-operative outcomes at 3-month follow up due to scope size. However, if same-day discharge is part of your postoperative pathway, the 28F scope may shorten length of stay and increase rates of successful same-day trial of void.


8 May 2023 in Journal of Endourology
Verified
Journal Article
Closed access
MHMitchell M. Huang
Mitchell M. Huang
NDNicholas Stewart Dean
Nicholas Stewart Dean
MAMark Assmus
Mark Assmus
MLMatthew S. Lee
Matthew S. Lee
JGJenny N. Guo
Jenny N. Guo
AKAmy Krambeck
Amy Krambeck
Introduction: Intradetrusor onabotulinumtoxinA (OTA) injection is a well-established treatment option for refractory overactive bladder (OAB), however its use at the time of holmium laser enucleation of the prostate (HoLEP) for men with bladder outlet obstruction (BOO) and storage symptoms has not been previously reported. Material and Methods: We retrospectively identified men with BOO and OAB who underwent treatment with 200U of intradetrusor OTA at the time of HoLEP. Patients were propensity score matched to a cohort of HoLEP-only patients based on age, Michigan Incontinence Symptom Index (M-ISI) score, pre-operative urinary retention, urge incontinence, and prostate size. Perioperative, post-operative, and patient-reported outcomes were examined between groups. Results: We identified 82 men who underwent HoLEP, including 41 patients in the OTA group and 41 patients in the control group. There was no difference in operative times (59 mins OTA vs 55 mins control, p=0.2), rates of successful same-day TOV (92% OTA vs. 94% control, p=0.7), or rates of same-day discharge (88% OTA vs. 85% control, p=0.6) between groups. There was no difference in temporary post-operative urinary retention (7% OTA vs. 2% control, p=0.3) between groups. Patients who received OTA injections had a significant reduction in their incontinence scores at 3-month follow-up (M-ISI -8, IQR: -13 to 0, p<0.001), while control patients did not (M-ISI -5, IQR: -8 to -1, p=0.2). There was no difference in rates of 90-day complications between groups (OTA 10% vs. control 5%, p=0.7). Conclusions: Intradetrusor OTA at the time of HoLEP is safe and is associated with improved urinary incontinence scores and AUA Symptom Score (AUASS). Rates of same-day discharge and successful same day TOV after HoLEP were not affected by OTA. These findings support the role of OTA as an adjunct to surgical intervention in men with incontinence related to OAB in the presence of BOO.